At the news
? NEUTRALIMPACT 2/10 8-K filed Jun 16, 2026 at 08:30 ET
Palvella Therapeutics held its 2026 Annual Meeting on June 10, 2026, where shareholders approved an amendment to the 2024 Equity Incentive Plan to increase authorized shares by 750,000 (approximately 5.2% of outstanding shares). All director nominees were elected, Ernst & Young was ratified as auditor, and advisory votes on executive compensation and frequency were approved. This is a routine governance filing with no material financial or operational impact.
- Shareholders approved an amendment to the 2024 Equity Incentive Plan, increasing authorized shares by 750,000.
- Class III directors George M. Jenkins, Todd C. Davis, and John Doux, M.D. were elected with strong support.
- Ernst & Young LLP was ratified as independent auditor for fiscal 2026 with 11,557,687 votes for.
- Advisory vote on named executive officer compensation passed with 10,008,180 votes for.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access